New insights into iron regulation and erythropoiesis

Current Opinion in Hematology

Volumn 22, Issue 3, 2015, Pages 199-205

  Kim, Airie ^a   Nemeth, Elizabeta ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

erythroferrone; erythropoiesis; GDF11; hepcidin; iron

Indexed keywords

ACONITATE HYDRATASE; ERYTHROFERRONE; ERYTHROPOIETIN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRON; IRON REGULATORY PROTEIN 1; PROTEIN; TWISTED GASTRULATION PROTEIN HOMOLOG 1; UNCLASSIFIED DRUG;

ENZYME INHIBITION; ERYTHROPOIESIS; HEMOGLOBIN SYNTHESIS; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON RESTRICTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; IRON OVERLOAD; METABOLISM; PHYSIOLOGY;

ERYTHROPOIESIS; HEPCIDINS; HUMANS; IRON; IRON OVERLOAD;

EID: 84928476752     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000132     Document Type: Review

References (67)

1. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta 2006; 1763:690-699.
2. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of ironinduced hepatic fibrogenesis. Semin Liver Dis 2005; 25:433-449.
3. Finch C. Regulators of iron balance in humans. Blood 1994; 84:1697-1702.
4. Ganz T, Nemeth E. Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med 2012; 2:a011668.
5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276:7806-7810.
6. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011; 2011:538-542.
7. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306:2090-2093.
8. Rivera S, Liu L, Nemeth E, et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005; 105:1797-1802.
9. Roy CN, Mak HH, Akpan I, et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007; 109:4038-4044.
10. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98:8780-8785.
11. Viatte L, Lesbordes-Brion JC, Lou DQ, et al. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood 2005; 105:4861-4864.
12. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33:21-22.
13. Corradini E, Rozier M, Meynard D, et al. Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology 2011; 141:1907-1914.
14. Ramos E, Kautz L, Rodriguez R, et al. Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology 2011; 53:1333-1341.
15. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011; 62:347-360.
16. Pak M, Lopez MA, Gabayan V, et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006; 108:3730-3735.
17. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271-1276.
18. Rodriguez R, Jung CL, Gabayan V, et al. Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun 2014; 82:745-752.
19. Armitage AE, Eddowes LA, Gileadi U, et al. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011; 118:4129-4139.
20. Mayeur C, Lohmeyer LK, Leyton P, et al. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. Blood 2014; 123:2261-2268.
21. Goodnough JB, Ramos E, Nemeth E, Ganz T. Inhibition of hepcidin transcription by growth factors. Hepatology 2012; 56:291-299.
22. Latour C, Kautz L, Besson-Fournier C, et al. Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin. Hepatology 2014; 59:683-694.
23. Vecchi C, Montosi G, Garuti C, et al. Gluconeogenic signals regulate iron homeostasis via hepcidin in mice. Gastroenterology 2014; 146:1060-1069.
24. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
25. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009; 113:5277-5286.
26. Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010; 116:3635-3644.
27. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009; 4:1384-1387.
28. Gardenghi S, Renaud TM, Meloni A, et al. Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. Blood 2014; 123:1137-1145.
29. Kim A, Fung E, Parikh SG, et al. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 2014; 123:1129-1136.
30. Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am 2014; 28:637-652; v.
31. Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with beta-thalassemia major: a longitudinal study. Blood 2013; 122:124-133.
32. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007; 92:583-588.
33. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia. Nat Med 2014; 20:398-407.
34. Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010; 16:177-182.
35. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest 2010; 120:4466-4477.
36. Casu CGS, Nemeth E, Ganz T, et al. Low dose minihepcidin peptide causes improvement of anemia by increased erythropoietic efficiency in a mouse model of thalassemia intermedia. Am J Hematol 2013; 88:E43.
37. Nai A, Pagani A, Mandelli G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood 2012; 119:5021-5029.
38. Schmidt PJ, Toudjarska I, Sendamarai AK, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood 2013; 121:1200-1208.
39. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest 2013; 123:1531-1541.
40. Shenoy N, Vallumsetla N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood 2014; 124:873-881.
41. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014; 46:678-684.
42. Kautz L, Jung G, Nemeth E, Ganz T. Erythroferrone contributes to recovery from anemia of inflammation. Blood 2014; 124:2569-2574.
43. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13:1096-1101.
44. Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008; 112:5241-5244.
45. Frazer DM, Wilkins SJ, Darshan D, et al. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression. Br J Haematol 2012; 157:615-626.
46. Tanno T, Rabel A, Lee YT, et al. Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion 2010; 50:1532-1535.
47. Theurl I, Finkenstedt A, Schroll A, et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol 2010; 148:449-455.
48. Tarkun P, Mehtap O, Atesoglu EB, et al. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol 2013; 91:228-235.
49. Casanovas G, Vujic Spasic M, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2013; 98:444-447.
50. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114:181-186.
51. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36:1573-1584.
52. ZhangDL,GhoshMC, Rouault TA. The physiological functions of iron regulatory proteins in iron homeostasis - an update. Front Pharmacol 2014; 5:124.
53. Rouault TA. Cell biology. An ancient gauge for iron. Science 2009; 326:676-677.
54. Anderson SA, Nizzi CP, Chang YI, et al. The IRP1-HIF-2alpha axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab 2013; 17:282-290.
55. Ghosh MC, Zhang DL, Jeong SY, et al. Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2a. Cell Metab 2013; 17:271-281.
56. Wilkinson N, Pantopoulos K. IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2alpha mRNA translation. Blood 2013; 122:1658-1668.
57. Talbot AL, Bullock GC, Delehanty LL, et al. Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling. PLoS One 2011; 6:e23850.
58. Richardson CL, Delehanty LL, Bullock GC, et al. Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response. J Clin Invest 2013; 123:3614-3623.
59. Bullock GC, Delehanty LL, Talbot AL, et al. Iron control of erythroid development by a novel aconitase-associated regulatory pathway. Blood 2010; 116:97-108.
60. Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013; 98:1667-1676.
61. Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009; 24:744-752.
62. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 2014; 20:408-414.
63. Langdon JM, Barkataki S, Berger AE, et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol 2015; 90:8-14.
64. Wu HH, Ivkovic S, Murray RC, et al. Autoregulation of neurogenesis by GDF11. Neuron 2003; 37:197-207.
65. Kim J, Wu HH, Lander AD, et al. GDF11 controls the timing of progenitor cell competence in developing retina. Science 2005; 308:1927-1930.
66. McPherron AC, Lawler AM, Lee SJ. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet 1999; 22:260-264.
67. Loffredo FS, Steinhauser ML, Jay SM, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013; 153:828-839.